Arbutus has moved into Part 3 of this clinical trial which evaluates repeat dosing of AB-101 for 28 days in patients with cHBV and expects to report preliminary data in the first half of next year.
Bonus Sep 11, 2018 Sep 13, 2018 Jul 24, 2018 Bonus Ratio: 1 share(s) for every 1 shares held Bonus Jan 02, 1995 Jan 24, 1995 Sep 28, 1995 Bonus Ratio: 1 share(s) for every 1 shares held Rights May 21, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback